Coherus Moves Ahead With Pegfilgrastim On-Body Injector Rival

Dominant Neulasta Onpro Commands More Than 50% Of Pegfilgrastim Market

 
• By Dean Rudge
  
competition
Coherus is eyeing a landmark approval for an on-body injector device • Source: Alamy

More from Biosimilars

More from Products